Global Antimicrobial Resistance Market was valued at US$ 9,390.00 Mn in 2020, estimated to reach US$ 13,800.00 Mn in 2027 with a CAGR of 4.68% from 2021-2027.
Market Drivers: Impact of Antimicrobial Resistance (AMR) market on healthcare industry
The emergence and spread of drug-resistant pathogens which have acquired new resistance mechanisms, leading to antimicrobial resistance, continues to threaten our ability to treat common infections. Especially alarming is the rapid global spread of multi- and pan-resistant bacteria (also known as “superbugs”) that cause infections that are not treatable with existing antimicrobial medicines such as antibiotics. Antibiotics are becoming increasingly ineffective as drug-resistance spreads globally leading to more difficult to treat infections and death. New antibacterial are urgently needed – for instance, to treat carbapenem-resistant gram-negative bacterial infections as identified in the WHO priority pathogen list. High burden of antibiotic-resistant infections and emergence of multi-drug resistant pathogens have been augmenting the market. These factors have impacted the growth of healthcare industry.
Get Free Sample Copy Of This Report @ https://qualiketresearch.com/request-sample/Antimicrobial-Resistance-Market/request-sample
Market key Players
Various key players are listed in this report such as Allecra Therapeutics, Procarta Biosystems, Achaogen, Inc., Basilea Pharmaceutica Ltd., MELINTA THERAPEUTICS, INC., Seres Therapeutics, PARATEK therapeutics, Entasis Therapeutics, Tetraphase Pharmaceuticals, Nabriva Therapeutics plc,etc.
Market Taxonomy
By Disease
- Acinetobacter baumannii (Carbapenem-Resistant)
- Pseudomonas aeruginosa (Carbapenem-Resistant)
- Staphylococcus Aureus (Methicillin-Resistant)
- E. coli/K. pneumoniae (Carbapenem-Resistant)
- Streptococcus pneumoniae (Penicillin-Non-Susceptible)
- Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
- Enterococcus faecium (Vancomycin-Resistant)
- Haemophilus Influenzae (Ampicillin-Resistant)
By Pathogen
- Acinetobacter baumannii (Carbapenem-Resistant)
- Pseudomonas aeruginosa (Carbapenem-Resistant)
- Staphylococcus Aureus (Methicillin-Resistant)
- E. coli/K. pneumoniae (Carbapenem-Resistant)
- Streptococcus pneumoniae (Penicillin-Non-Susceptible)
- Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)
- Enterococcus faecium (Vancomycin-Resistant)
- Haemophilus Influenzae (Ampicillin-Resistant)
By Drug Class
- Oxazolidinones
- Lipoglycopeptides
- Tetracyclines
- Cephalosporins
- Combination
- Others
By Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Inquire about this report @ https://qualiketresearch.com/request-sample/Antimicrobial-Resistance-Market/inquire-before-buying
Recent Developments:
In 2018: A Clostridium difficile infection (CDI) was launched in 2018 by the ACX–362E Pharmaceuticals, an approved antibiotic candidate from the US Food and Drug Administration.
In 2012: The GAIN Act, adopted in 2012 as an expansion of the United States, is now the generation of antibiotic stimuli. Safety and Innovation Act on Food and Drug Administration. The law seeks to encourage the creation of fresh therapies to increase antibiotic resistant diseases and their severity.
Inquire To Know More About This Report @ https://qualiketresearch.com/request-sample/Antimicrobial-Resistance-Market/inquire-before-buying